Anti-SPART/ SPG20/ TAHCCP1 monoclonal antibody
Anti-SPART/ SPG20/ TAHCCP1 antibody for FACS & in-vivo assay
Go to SPART/SPART products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP2335-Ab-1/ GM-Tg-hg-MP2335-Ab-2 | Anti-Human SPART monoclonal antibody | Human |
GM-Tg-rg-MP2335-Ab-1/ GM-Tg-rg-MP2335-Ab-2 | Anti-Rat SPART monoclonal antibody | Rat |
GM-Tg-mg-MP2335-Ab-1/ GM-Tg-mg-MP2335-Ab-2 | Anti-Mouse SPART monoclonal antibody | Mouse |
GM-Tg-cynog-MP2335-Ab-1/ GM-Tg-cynog-MP2335-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SPART monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP2335-Ab-1/ GM-Tg-felg-MP2335-Ab-2 | Anti-Feline SPART monoclonal antibody | Feline |
GM-Tg-cang-MP2335-Ab-1/ GM-Tg-cang-MP2335-Ab-2 | Anti-Canine SPART monoclonal antibody | Canine |
GM-Tg-bovg-MP2335-Ab-1/ GM-Tg-bovg-MP2335-Ab-2 | Anti-Bovine SPART monoclonal antibody | Bovine |
GM-Tg-equg-MP2335-Ab-1/ GM-Tg-equg-MP2335-Ab-2 | Anti-Equine SPART monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP2335-Ab-1/ GM-Tg-hg-MP2335-Ab-2; GM-Tg-rg-MP2335-Ab-1/ GM-Tg-rg-MP2335-Ab-2; GM-Tg-mg-MP2335-Ab-1/ GM-Tg-mg-MP2335-Ab-2; GM-Tg-cynog-MP2335-Ab-1/ GM-Tg-cynog-MP2335-Ab-2; GM-Tg-felg-MP2335-Ab-1/ GM-Tg-felg-MP2335-Ab-2; GM-Tg-cang-MP2335-Ab-1/ GM-Tg-cang-MP2335-Ab-2; GM-Tg-bovg-MP2335-Ab-1/ GM-Tg-bovg-MP2335-Ab-2; GM-Tg-equg-MP2335-Ab-1/ GM-Tg-equg-MP2335-Ab-2 |
Products Name | Anti-SPART monoclonal antibody |
Format | mab |
Target Name | SPART |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-SPART benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species SPART/ SPG20/ TAHCCP1 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP2335 |
Target Name | SPART |
Gene ID | 23111,229285,295053,693663,477303,101085013,534027,100062426 |
Gene Symbol and Synonyms | mKIAA0610,SPART,SPG20,TAHCCP1 |
Uniprot Accession | Q8N0X7,A0JNJ3 |
Uniprot Entry Name | SPART_HUMAN,SPART_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000133104 |
Target Classification | N/A |
The target: SPART, gene name: SPART, also named as SPG20, TAHCCP1. This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome). [provided by RefSeq, Nov 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.